Alzheimer’s Disease: The Role of Amyloid Beta 42/40 in Risk Assessment

Fri., Nov. 10, 2017
12:00 PM ET/9:00 AM PT

Click here to register for this live educational webinar where Dr Clarke will discuss new innovations in AD biomarker-assay development and utilization, driven by the use of tandem mass spectrometry in lieu of previously used ELISA methods, compare the clinical impact of having a Aβ 42/40 ratio vs traditional biomarker assays and describe the clinical utility of testing Aβ 42/40 cerebrospinal fluid ratios, and using an overall risk assessment score, to support the differential diagnosis of patients with mild cognitive 

Nigel J. Clarke, 

Vice President, Advanced Technology

Quest Diagnostics Nichols Institute

San Juan Capistrano, CA

ONE contact hour toward ASCLS P.A.C.E. ® credit will be available to participating laboratory professionals who attend the webinar and complete the post evaluation.

Audience: Neurologists, Internal Medicine, Nurse Practitioners, Physician Assistants, Adult Medicine, Geriatrics, Lab Professionals 

INVITATION - Download printable invitation PDF